Hepatitis Archives - O'Neill : O'Neill

The Latest From O'Neill

January 1, 2023

Hepatitis C is a slow-moving killer that can be stopped. What’s getting in the way?

October 28, 2022

Investing in Community Care Is an Important Goal and Need for Eliminating Hepatitis C in the United States: An Abolitionist Perspective

October 1, 2022

Celebrating Hispanic Heritage Month with Sonia Butler Canzater ’15

Our Experts

Sonia L. Canzater Associate Director

Initiatives

June 8, 2021

Infectious Diseases

Building robust and equitable legal, regulatory, and policy responses to the epidemics of HIV and hepatitis in the United States.

Learn More

Projects

Hepatitis Policy Project

Working at the intersection of law and policy with the goal of eliminating viral hepatitis in the United States.

Learn More

Opinion & Analysis See All

December 21, 2021

Hepatitis C Treatment is Dropping: How Can We Reverse the Downward Trajectory?

November 9, 2021

Looking Beyond Innovative Payment Models for Hepatitis C Virus Elimination

May 19, 2021

Get Tested for Viral Hepatitis and Know Your Status

July 28, 2020

Who Bears the Burden?: How Current HCV Elimination Efforts Are Likely to Exacerbate the Existing HCV Burden on Vulnerable LGBT and Immigrant Populations

Press See All

In The News

Hepatitis C is a slow-moving killer that can be stopped. What’s getting in the way?

In The News

Celebrating Hispanic Heritage Month with Sonia Butler Canzater ’15

In The News

With a promising new plan to pay for pricey cures, two states set out to eliminate hepatitis C. But cost hasn’t been the biggest problem

In The News

Hep ElimiNATION Updates State Grades & Publishes New List of Resources

Publications See All

Journal Article

Investing in Community Care Is an Important Goal and Need for Eliminating Hepatitis C in the United States: An Abolitionist Perspective

Big Ideas

Prioritizing The Funding of Harm Reduction Efforts Using Opioid Litigation Proceeds: A Tool To Support Viral Hepatitis Elimination in the United States

Op-Ed

States Must Act Against Viral Hepatitis Now To Eliminate the Ongoing Epidemic by 2030

Quick Take

Harm Reduction Is Essential to U.S. Drug Policy